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Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus-associated disease with high prevalence in Southern Chinese. Using
multiparametric flow cytometry, we identified significant expansions of circulating naı ¨ve and memory CD4þCD25
high T cells in 56
NPC patients compared with healthy age- and sex-matched controls. These were regulatory T cells (Treg), as they overexpressed
Foxp3 and GITR, and demonstrated enhanced suppressive activities against autologous CD4þCD25  T-cell proliferation in
functional studies on five patients. Abundant intraepithelial infiltrations of Treg with very high levels of Foxp3 expression and absence
of CCR7 expression were also detected in five primary tumours. Our current study is the first to demonstrate an expansion of
functional Treg in the circulation of NPC patients and the presence of infiltrating Treg in the tumour microenvironment. As Treg may
play an important role in suppressing antitumour immunity, our findings provide critical insights for clinical management of NPC.
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Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-
associated malignant disease with high prevalence in Southern
Chinese. Despite favourable responses to radio-chemotherapy in
most patients with early disease, a significant number of patients
present with metastatic or refractory disease or develop relapses
(Teo et al, 2006). Thus, alternative therapeutic approaches need to
be established. One approach is the development of immuno-
therapy specifically targeting NPC cells for immune destruction by
EBV-specific cytotoxic T lymphocytes. Thus far, limited studies
reported variable clinical responses (Chua et al, 2001; Comoli et al,
2005; Straathof et al, 2005).
CD4þCD25þ regulatory T cells (Treg) can suppress the
activation and proliferation of CD4þ and CD8þ T cells (Piccirillo
and Shevach, 2001; Woo et al, 2002) and play an important role
in controlling autoreactive T cells. However, for several types of
human cancer, an increase of Treg in the peripheral blood (PB)
and the presence of Treg at the tumour site has been reported
(Woo et al, 2001, 2002; Liyanage et al, 2002; Wolf et al, 2003;
Ormandy et al, 2005; Schaefer et al, 2005), indicating that these
cells may also suppress T-cell-mediated antitumour immunity
(Piccirillo and Shevach, 2001; Curiel et al, 2004). Understanding
the role of Treg in NPC patients has important implications for
disease management, including the development of successful
T-cell immunotherapy.
MATERIALS AND METHODS
Patient recruitment
With informed consent, a total of 57 poorly differentiated and
undifferentiated NPC patients were prospectively recruited at
diagnosis at the Prince of Wales Hospital (2005–2006), including
four patients with stage I tumour, 18 with stage II, 17 with stage III,
and 18 with stage IV tumours. All of the tumours were confirmed
to be EBV-positive by EBER in situ hybridisation. Five patients
were recruited for tumour biopsies collection. For control group,
56 sex- and age-matched healthy blood donors from the Hong
Kong Red Cross Blood transfusion Service were used.
Multicolour flow cytometric analysis
Peripheral blood mononuclear cells (PBMNC) were isolated
from freshly drawn blood by centrifugation on Ficoll–Hypaque
gradient solution (Pharmacia, Uppsala, Sweden). Tumour biopsies
were dissociated into single cell suspensions with collagenase
digestion and/or mechanical dissociation. The PBMNC and
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ssuspended cells were immunostained with fluorochrome-conju-
gated anti-human antibodies for 25min at 41C. For intracellular
antigens, the cells were fixed and permeabilised with Becton
Dickinsont (BD) fix/perm solution (BD Biosciences, Bedford, MA,
USA) before immunostaining. The panel of antibody combinations
conjugated to fluorescein isothiocyanate (FITC), phycoerythrin
(PE), phycoerythrin-cyanin 5 (PECy5), and allophycocyanin
(APC)/AlexaFluor647 (AF647) were (1) CD25-FITC/CD3-PE/CD4-
PECy5/CD8-APC, (2) CD25-FITC/CD45RO-PE/CD4-PECy5, (3)
CD25-FITC/CCR7-PE/CD4-PECY5/CD152-APC, and (4) CD25-
FITC/GITR-PE/CD4-PECy5/Foxp3-AF647. Cell acquisition was
performed using a BD FACSCalibur flow cytometer. Data of
X200000 lymphocytes gated by forward and side scatter proper-
ties were collected for the examination of various marker
expressions in the cells. Flow data were analysed using FlowJo
r
Analysis Software (Treestar Inc., Ashland, OR, USA) for gating
different populations of T-cell subsets and determination of
expression levels of various markers in Treg cells. Various T-cell
subset data as the cell percentage in total lymphocytes and the
marker expression levels of CD4þCD25 Treg cells between NPC
patients and sex-and age-matched healthy control were statistically
analysed using Mann–Whitney U test for nonparametric inde-
pendent group comparisons.
T-cell proliferation suppression assay
CD4þ T-cells were purified from PBMNC of five patients and four
healthy blood donors with negative-immunomagnetic sorting
using untouched CD4þ T-cell kit according to manufacturers’
recommended protocol (Miltenyi, Germany). The cells were
further positive-immunosorted using CD25 microbeads (Miltenyi)
to isolate the CD4þCD25þ T-cell population. The CD4þCD25-
T-cells were collected in the negative fraction. The CD4þCD25 
T-cells (2 10
5/ml) were plated onto BioCoat T-cell activation
plates (BD Biosciences, Bedford, MA, USA). Autologous
CD4þCD25þ T cells were added at ratios of 1:0, 1:1, 1:2,
1:5, and 0:1 to CD4þCD25  T cells. After 4 days, satisfactory
cell viability was confirmed by using trypan blue exclusion
method, and T-cell proliferation was assessed in triplicate by
WST-1 cell proliferation assay (Roche, Germany).
RESULTS AND DISCUSSIONS
Reduced circulating CD4þ T cells in NPC patients
In this study, we first characterised the T-cell populations in PB of
NPC patients. As shown in Table 1, the percentage of CD4þ
Table 1 Characterization of T-cell populations in the peripheral blood of 56 NPC patients and 56 age- and sex-matched healthy blood donor controls
(N¼56) Normal (%)
a NPC (%)
a P-value
(a) T-cell subsets
CD3+CD4+
b 21.779.9 17.8 710.1 0.0321
CD3+CD8+
b 13.276.7 12.077.0 0.3130
CD4+CD45RO+ 18.278.5 12.676.7 0.0005
CD4+CD45RO- 9.475.7 6.976.0 0.0041
CD4+CD25+ 8.873.8 13.676.7 0.0001
CD4+CD25
high 4.073.6 8.275.9 0.0002
CD4+CD25
highCD45RO+ 2.772.4 6.475.1 o0.0001
CD4+CD25
highCD45RO  1.371.6 2.672.7 0.0052
Cells with positive expression Signal levels
(N¼56) Normal (%) NPC (%) Normal (MFI) NPC (MFI) P-value
(b) Treg marker expressions in circulating CD4+CD25
high cells
CD4+CD25
high CTLA4/CD152 87.6711.2 94.6713.3 406731 420728 0.1203
CD4+CD25
high GITR 99.970.3 98.0713.5 526768 606748 o0.0001
CD4+CD25
high Foxp3 90.978.1 94.2713.7 5227147 6027110 0.0005
CD4+CD25
high CCR7 93.777.2 92.2720.6 414742 423748 0.2443
aDenotes % in total lymphocytes.
bThe CD4/CD8 ratio in NPC patients (1.270.4) was significantly reduced as compared with that of normal controls (1.970.9) (Po0.0001).
Bold prints in % and P-values represent statistically significant differences. MFI refers to mean fluorescence intensity. NPC¼nasopharyngeal carcinoma.
Figure 1 Characterisation of the Treg populations in PB of NPC patients and normal healthy blood donors. Gating of CD4þCD25þ (R2 and R3 gated
regions) and CD4þCD25
high (R3 gated region) T cells of representative normal individual control (A) and NPC patient (B) are presented. The Foxp3-
expressed T cells (coloured in black) were back-gated among the lymphocytes (coloured in grey) in the FASC plots. Percentages of circulating
CD3þCD4þCD25þ T cells (C) and CD3þCD8þCD25þ T cells (D) in lymphocytes were determined in 56 NPC patients (’) and 56 age- and sex-
matched normal controls (m).The CD3þCD4þCD25
high T-cell populations were also gated and the percentages between two groups were compared
(E). The horizontal lines represent the mean values of the cell percentages. Expression levels of various Treg markers such as CTLA-4/CD152 (F), GITR (G),
and Foxp3 (H) in the cells were also examined. Expression levels in terms of mean fluorescence intensity of these markers in representative cases of normal
(yellow line) and NPC patients (green line) are shown. The differences in mean values of two groups were statistically analysed by Mann–Whitney U test
and the significance level is set at 0.05. Asterisks indicate that the mean percentages of T-cell subsets in lymphocytes of NPC patients showed statistically
significant differences as compared to those in controls. (I) Functional characterisation of circulating Treg in healthy volunteers (N¼4) and NPC patients
(N¼5, four from the group of 56 patients and one was also analysed for TIL but not for PB Treg). CD4þCD25  T cells (210
5/ml) were challenged with
CD3 antibody and levels of cellular proliferation determined in the presence or absence of autologous Treg added at the ratios indicated. Mean levels of
cellular proliferation are expressed as a percentage of that seen in cultures without the addition of Tregs. The mean percentages of CD4þCD25þ Treg,
which can achieve 50% inhibition of autologous CD4þCD25  T-cell proliferation, were compared (right). The standard deviations of the percentages
were presented as ‘T’ bars.
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s(P¼0.0321) but not CD8þ T cells were significantly decreased in
NPC patients as compared with those in sex- and age-matched
healthy controls. As the lymphocyte counts of NPC patients
(1.770.6 10
9/l) were similar to those in the controls
(1.870.4 10
9/l), this represents a reduction in CD4þ T-cell
numbers in the PB of NPC patients. This was true for CD4þ cells
in both memory CD4þCD45ROþ (P¼0.0005) and naı ¨ve
CD4þCR45RO  (P¼0.0041) T-cell populations (Table 1).
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high regulatory T cells
in NPC patients
Despite this reduction in the number of circulating CD4þ T cells
in NPC patients vs healthy donors, we found an increase in the
subset of circulating CD4þ T cells that expressed CD25
(P¼0.0001). No such increase was seen for CD8þCD25þ T cells
(P¼0.4366) (Table 1 and Figure 1A–D). A previous study has
demonstrated elevated serum transforming growth factor-b (TGF-
b) levels in NPC patients (Xu et al, 1999). Thus, it is of special
interest to note that TGF-b can generate and expand
CD4þCD25þ Treg from human PB (Yamagiwa et al, 2001). To
exclude the population of activated T cells, which might express
low levels of CD25 in human PB (Baecher-Allan et al, 2004), cells
expressing high levels of CD25 were regated and quantified as
Treg. Again, significant increase in CD4þCD25
high Treg was
observed in the patients (Table 1 and Figure 1E). This increase did
not correlate with NPC staging, tumour size, lymph node status, or
the presence of metastasis (data not shown).
Characterisation of circulating Treg in NPC patients
Using multiparametric flow cytometric analyses, we demonstrated
that the majority (B90%) of CD4þCD25
high cells in both NPC
patients and controls expressed various intracellular and surface
biomarkers characteristic of Treg. These biomarkers included the
cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4; CD152),
the glucocorticoid-induced tumour necrosis factor receptor
family-related protein (GITR), and the forkhead box transcrip-
tional factor (Foxp3) (Table 1b). Expression of these markers by
CD4þCD25
high cells strongly suggests that they are Treg. We also
noted that levels of expression of GITR and Foxp3 were
significantly higher in CD4þCD25
high cells from patients than
controls (Figure 1F–H; Table 1b).
It has been demonstrated that Treg is anergic, and in vitro
inhibition of CD4þCD25  T-cell proliferation by purified human
CD4þCD25þ Treg is linked to their upregulation of Foxp3
mRNA and protein (Baratelli et al, 2005). Thus, we further
examined and compared the suppressive activity of CD4þCD25þ
Treg cells in five NPC patients and four healthy volunteers. We
confirmed the anergic nature of the Treg in both NPC patients and
controls. More importantly, we found that the doses of Treg which
could achieve 50% inhibition of autologous CD4þCD25  T-cell
proliferation were significantly lower (P¼0.0159) for NPC patients
(23.8979.44%) than for controls (60.4076.87%) (Figure 1I). The
increased suppressive activity seen in CD4þCD25þ T cells from
NPC patients may reflect the greater number of CD4þCD25
high
cells and/or the increased expression of Foxp3 and GITR in these
cells compared with controls.
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Figure 2 Characterising Treg in TIL and PB. The biopsy specimen was mechanically dissociated, fixed, and immunostained with the antibodies to CD4,
CD25, and Foxp3 or CCR7. The suspended cells were analysed by flow cytometry gating on lymphocytes. Flow cytometric analysis on PB was as previously
described in Figure 1. Two representative cases (NPC1 and NPC2) are shown. The percentage of Tregs was explored in TIL(’) and PB (&) analysing the
CD4þCD25þ gated population (R2 and R3) and the CD4þCD25
high population (R3 alone). Expression of Foxp3 and CCR7 in CD4þCD25
high Treg
from both TIL and PB are presented as histograms. For these histograms, they are the composite of two different FACS plots, one from the data of PB
(white coloured peak) and another from TIL (black coloured peak), highlighting the loss of CCR7 expression and increased Foxp3 expression in the
CD4
þCD25
high of TIL as the shifts of those peaks. The horizontal line represents the cutoff of positivity defined using an isotype-matched control antibody.
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high Treg belonged to the
memory T-cell compartments (Dieckmann et al, 2001; Taams et al,
2001). However, we found that the expanded Treg not only
exhibited CD45ROþ memory phenotype (B70%), as in previous
studies (17–18), but also CD45RO- naı ¨ve phenotype (B30%)
(Table 1a). Interestingly, Beyer et al (2006) recently also
demonstrated an in vivo peripheral expansion of naı ¨ve
CD4þCD25
high Foxp3þ Treg in multiple myeloma patients.
CD4þ T cells expressing the chemokine receptor CCR7 are able
to migrate to secondary lymphoid organs and/or tissue (Bromley
et al, 2005). Thus, to determine the migratory phenotype of the
expanded circulating Treg in our NPC patients, we studied their
expression of CCR7. Our data revealed that 93.7 and 92.2% of
circulating Treg, respectively, in controls and NPC patients
expressed similar levels of CCR7 (Table 1b), indicating a lymph
node-homing capacity for the expanded Treg in our NPC patients.
To determine if Treg infiltrated the tumour site, we examined
the tumour infiltrating lymphocytes (TIL) in NPC biopsies from
five patients. We found that 10.9671.09% of TIL exhibited a
CD4þCD25
highFoxp3þ Treg immunophenotype. Interestingly,
levels of Foxp3 expression in CD4þCD25
high TIL were consider-
ably higher than those seen in circulating CD4þCD25
high cells.
Furthermore, CD4þCD25
high TIL did not express CCR7. (Figure 2;
Table 2). The relatively low numbers of TIL that can be obtained
from NPC biopsies did not allow functional tests on this
population, but it is interesting to speculate that elevated levels
of Foxp3 expression correlates with increased suppressive activity.
The absence of CCR7 indicates that the migratory properties of
these cells has been changed, so that they no longer home to lymph
nodes but now migrate to the tumour tissue
In conclusion, we have demonstrated an increase of
Foxp3þCD4þCD25
high Treg in PB and tumour sites in NPC
patients. The expanded Treg in the circulation also showed
enhanced suppressive activity on CD4þCD25  T-cell prolifera-
tions. The increase of this functional Treg population might reduce
T-cell-mediated antitumour immunity as represented by the
significant decrease in CD4þ T-cell populations in the NPC
patients. Thus, the present findings have provided important
information and insight into the future design of immunother-
apeutic strategies for NPC.
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